吉非替尼辅助常规化疗对非小细胞肺癌患者临床疗效与肿瘤标记物的影响  

Effect of Gefitinib Adjuvant Conventional Chemotherapy on Clinical Efficacy and Tumor Markers in Patients with Non-Small Cell Lung Cancer

作　　者：何亚楠 孙彩云 肖书超 He Ya-nan;Sun Cai-yun;Xiao Shu-chao(Department of Pharmacy,Kaifeng Cancer Hospital,Kaifeng 475000,Henan,China;Department of Internal Medicine,Kaifeng Cancer Hospital,Kaifeng 475000,Henan,China)

机构地区：[1]开封市肿瘤医院药剂科,河南开封475000 [2]开封市肿瘤医院内二科,河南开封475000

出　　处：《四川生理科学杂志》2025年第4期894-896,共3页

摘　　要：目的:探讨与分析吉非替尼辅助常规化疗对非小细胞肺癌患者临床疗效与肿瘤标记物的影响。方法:选取2022年7月至2024年8月本院收治的中晚期非小细胞肺癌患者92例作为研究对象,根据随机信封抽签原则把92例患者分为吉非替尼组46例与传统组46例。对照组给予常规化疗,吉非替尼组在对照组治疗的基础上给予吉非替尼辅助治疗,两组都治疗观察3个疗程,记录两组疗效与血清癌胚抗原(Carcinoembryonic antigen,CEA)、鳞状细胞癌抗原(Squamous cell carcinoma antigen,SCCA)表达变化情况。结果:治疗3个疗程后吉非替尼组的总有效率为82.61%,对照组为52.17%,吉非替尼组显著高于对照组(P<0.05)。吉非替尼组治疗3个疗程期间的皮疹、腹泻、恶心呕吐、肝功能异常等毒副反应发生率分别为8.70%、8.70%、10.87%、6.52%,传统组分别为8.70%、10.87%、8.70%、6.52%,吉非替尼组与传统组相比无明显变化(P>0.05)两组治疗3个疗程后的血清CEA、SCCA含量都显著低于治疗前(P<0.05),吉非替尼组治疗3个疗程后的血清CEA、SCCA含量都与传统组相比也有统计学意义的降低(P<0.05)。所有患者随访到2024年12月1日,两组随访时间对比无明显差异(P>0.05),吉非替尼组的复发率为2.17%,传统组为17.39%,吉非替尼组与传统组相比有统计学意义的降低(P<0.05)。结论:吉非替尼辅助常规化疗在非小细胞肺癌患者的应用能提高治疗效果,且不会增加毒副反应发生率,还可降低患者对的血清CEA、SCCA含量与复发率。Objective:To explore and analyze the effect of gefitinib adjuvant conventional chemotherapy on clinical efficacy and tumor markers in patients with non-small cell lung cancer.Methods:92 patients with advanced non-small cell lung cancer admitted to our hospital from July 2022 to August 2024 were selected as the research subjects.According to the principle of random envelope drawing,the 92 patients were divided into a gefitinib group of 46 cases and a traditional group of 46 cases.The control group received conventional chemotherapy,and the gefitinib group was given gefitinib adjuvant therapy based on the treatment of the control group.Both groups were observed for 3 courses of treatment,and the efficacy and changes in serum carcinoembryonic antigen(CEA)and squamous cell carcinoma antigen(SCCA)expression were recorded.Results:After 3 courses of treatment,the total effective rate of the gefitinib group was 82.61%,while the control group was 52.17%.The gefitinib group was significantly higher than the control group(P<0.05).The incidence of toxic side effects such as rash,diarrhea,nausea and vomiting,and liver dysfunction during three treatment courses in the gefitinib group was 8.70%,8.70%,10.87%,and 6.52%,respectively,while in the traditional group it was 8.70%,10.87%,8.70%,and 6.52%,respectively.There was no significant change in the gefitinib group compared to the traditional group(P>0.05).After three treatment courses,the serum CEA and SCCA levels in both groups were significantly lower than before treatment(P<0.05),and the serum CEA and SCCA levels in the gefitinib group were also significantly reduced compared to the traditional group after three treatment courses(P<0.05).All patients were followed up until December 1,2024,and there was no significant difference in follow-up time between the two groups(P>0.05).The recurrence rate of the gefitinib group was 2.17%,while that of the traditional group was 17.39%.There was a statistically significant decrease in the gefitinib group compared to the traditional group(

关 键 词：吉非替尼 非小细胞肺癌 毒副反应 肿瘤标记物 临床疗效 

分 类 号：R734.2[医药卫生—肿瘤]